Chipscreen Biosciences, Ltd.

This study tests a new combination of three drugs (tucidinostat, sintilimab, and bevacizumab) against a standard single drug (fruquintinib) in people with a common type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if th…

This study tests whether adding the drug tucidinostat to standard chemotherapy (CHOP) can help people with a rare type of lymphoma (PTCL-TFH) live longer without their cancer getting worse. About 224 adults with newly diagnosed disease will be randomly assigned to get either tuci…

This study is testing a new drug called CS23546 in people with advanced solid tumors or lymphoma that have not responded to or cannot tolerate standard treatments. The main goals are to find a safe dose and understand how the drug works in the body. About 156 participants will ta…

This study tests an experimental pill called CS32582 in adults with moderate to severe plaque psoriasis. The trial has two parts: a small dose-finding phase and a larger 12-week treatment phase involving about 200 people. Researchers will check if the drug safely reduces skin sym…